Wednesday, March 13, 2013

NOVARTIS - Sandoz Launches new ready to use formulation of Argatroban Injection

Sandoz has launched argatroban injection (in sodium chloride), the first ready-to-use alternative to Pfizer’s concentrate formulation, following the US Food and Drug Administration (FDA) approval of its  New Drug Application. According to IMS Health, US sales for Pfizer’s Argatroban Injection were
approximately USD 146 million for the 12 months ending in February 2011. Sandoz is marketing argatroban injection (in sodium chloride) in packages of two 125mg/125mL single-use vials. Other geneirc players which are also selling argatroban injection include Eagle Pharma and Hikma.

Argatroban is indicated as an anticoagulant for the prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia. Argatroban injection is also indicated as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI) with, or who are at risk for, heparin-induced thrombocytopenia.






Enter your email address:


Delivered by FeedBurner